Tetherex Pharmaceuticals: Oklahoma City-based biotech company raises $50 million for clinical trials
The money will be used to conduct trials on two applications of its SelK2 antibody.
Read full article »
Tetherex Pharmaceuticals focuses on the development of novel selectin inhibitor products to treat thrombosis, inflammatory diseases and cancer.
Read more